Oxybutynin chloride, extended-release — Competitive Intelligence Brief

Oxybutynin chloride, extended-release (Oxybutynin chloride, extended-release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Urology.

marketed Anticholinergic agent M3 muscarinic acetylcholine receptor Urology Small molecule

Target snapshot

Oxybutynin chloride, extended-release (Oxybutynin chloride, extended-release) — US Department of Veterans Affairs. Oxybutynin chloride is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxybutynin chloride, extended-release TARGET	Oxybutynin chloride, extended-release	US Department of Veterans Affairs	marketed	Anticholinergic agent	M3 muscarinic acetylcholine receptor
Spiriva HandiHaler	Spiriva HandiHaler	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic acetylcholine receptor
solifenacin succinate suspension	solifenacin succinate suspension	Astellas Pharma Inc	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Detrol LA	Detrol LA	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic acetylcholine receptors
Solifenacin PO	Solifenacin PO	Seattle Urology Research Center	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor
salbutamol + ipratropium bromide nebules	salbutamol + ipratropium bromide nebules	Imperial College London	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class